Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Early-Phase Exploratory Clinical Study of JY231 Injection in Relapsed/Refractory B-Cell Lymphoma/Leukemia: Safety, Tolerability, and Preliminary Efficacy

NCT06890065 is registered in ClinicalTrials.gov with Shenzhen Genocury Biotech Co., Ltd. as lead sponsor.

NCT NCT06890065
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06890065 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Early-Phase Exploratory Clinical Study of JY231 Injection in Relapsed/Refractory B-Cell Lymphoma/Leukemia: Safety, Tolerability, and Preliminary Efficacy
Lead sponsor
Shenzhen Genocury Biotech Co., Ltd.
Phase
Not applicable
Overall status
Recruiting
Start date
March 1, 2025
Completion date
December 31, 2027
Enrollment
20 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

b acute lymphoblastic leukemia, b-non hodgkin lymphoma